CRP and COVID-19: In contrast, a recent study demonstrated that Tocilizumab/Infliximab treatment alongside standard care significantly reduced certain inflammatory markers, including CRP, LDH, absolute lymphocyte count, and NLR compared to Tocilizumab plus standard care in moderate/severe hospitalized COVID-19 patients.